

## HR 1672

Maintaining Investments in New Innovation Act

**Congress:** 119 (2025–2027, Current)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Feb 27, 2025

**Current Status:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

**Latest Action:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (Feb 27, 2025)

**Official Text:** <https://www.congress.gov/bill/119th-congress/house-bill/1672>

### Sponsor

---

**Name:** Rep. Davis, Donald G. [D-NC-1]

**Party:** Democratic • **State:** NC • **Chamber:** House

## Cosponsors (39 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Allen, Rick W. [R-GA-12]	R · GA		Feb 27, 2025
Rep. Bean, Aaron [R-FL-4]	R · FL		Feb 27, 2025
Rep. Crenshaw, Dan [R-TX-2]	R · TX		Feb 27, 2025
Rep. Gottheimer, Josh [D-NJ-5]	D · NJ		Feb 27, 2025
Rep. Hudson, Richard [R-NC-9]	R · NC		Feb 27, 2025
Rep. Joyce, John [R-PA-13]	R · PA		Feb 27, 2025
Rep. Miller-Meeks, Mariannette [R-IA-1]	R · IA		Feb 27, 2025
Rep. Moore, Blake D. [R-UT-1]	R · UT		Feb 27, 2025
Rep. Morelle, Joseph D. [D-NY-25]	D · NY		Feb 27, 2025
Rep. Peters, Scott H. [D-CA-50]	D · CA		Feb 27, 2025
Rep. Tenney, Claudia [R-NY-24]	R · NY		Feb 27, 2025
Rep. Van Duyne, Beth [R-TX-24]	R · TX		Feb 27, 2025
Rep. Yakym, Rudy [R-IN-2]	R · IN		Feb 27, 2025
Rep. Dunn, Neal P. [R-FL-2]	R · FL		Mar 27, 2025
Rep. Hern, Kevin [R-OK-1]	R · OK		Apr 9, 2025
Rep. Carey, Mike [R-OH-15]	R · OH		Apr 10, 2025
Rep. Shreve, Jefferson [R-IN-6]	R · IN		May 9, 2025
Rep. Pfluger, August [R-TX-11]	R · TX		May 13, 2025
Rep. Sessions, Pete [R-TX-17]	R · TX		Jun 4, 2025
Rep. McDowell, Addison P. [R-NC-6]	R · NC		Jun 10, 2025
Rep. Kelly, Mike [R-PA-16]	R · PA		Sep 2, 2025
Rep. Fleischmann, Charles J. "Chuck" [R-TN-3]	R · TN		Sep 17, 2025
Rep. Malliotakis, Nicole [R-NY-11]	R · NY		Sep 30, 2025
Rep. Meuser, Daniel [R-PA-9]	R · PA		Sep 30, 2025
Rep. Pettersen, Brittany [D-CO-7]	D · CO		Sep 30, 2025
Rep. Balderson, Troy [R-OH-12]	R · OH		Oct 3, 2025
Rep. Moore, Tim [R-NC-14]	R · NC		Oct 17, 2025
Rep. Calvert, Ken [R-CA-41]	R · CA		Oct 31, 2025
Rep. Edwards, Chuck [R-NC-11]	R · NC		Oct 31, 2025
Rep. Moolenaar, John R. [R-MI-2]	R · MI		Oct 31, 2025
Rep. Weber, Randy K. Sr. [R-TX-14]	R · TX		Oct 31, 2025
Rep. Fong, Vince [R-CA-20]	R · CA		Nov 4, 2025
Rep. Jack, Brian [R-GA-3]	R · GA		Nov 10, 2025
Rep. Moran, Nathaniel [R-TX-1]	R · TX		Nov 17, 2025
Rep. Haridopolos, Mike [R-FL-8]	R · FL		Nov 21, 2025
Rep. Kean, Thomas H. [R-NJ-7]	R · NJ		Nov 21, 2025
Rep. Lee, Laurel M. [R-FL-15]	R · FL		Nov 21, 2025
Rep. Hinson, Ashley [R-IA-2]	R · IA		Dec 4, 2025
Rep. Mullin, Kevin [D-CA-15]	D · CA		Dec 9, 2025

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Feb 27, 2025
Ways and Means Committee	House	Referred To	Feb 27, 2025

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Feb 27, 2025)

Maintaining Investments in New Innovation Act

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

## Actions Timeline

---

- **Feb 27, 2025:** Introduced in House
- **Feb 27, 2025:** Introduced in House
- **Feb 27, 2025:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Feb 27, 2025:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Feb 27, 2025:** Introduced in House
- **Feb 27, 2025:** Introduced in House
- **Feb 27, 2025:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Feb 27, 2025:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Feb 27, 2025:** Introduced in House
- **Feb 27, 2025:** Introduced in House
- **Feb 27, 2025:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Feb 27, 2025:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Feb 27, 2025:** Introduced in House
- **Feb 27, 2025:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.